MeiraGTx Ocular UK Ltd clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 0 with minor changes only.

1. Notable

   Follow-up Gene Therapy Trial · X-linked Retinitis Pigmentosa…Follow-up Gene Therapy Trial · X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

   Sponsor changed: Janssen Research & Development, LLC to MeiraGTx Ocular UK Ltd

   MeiraGTx Ocular UK Ltd·Phase 3· NCT04794101· Registry history of NCT04794101 on ClinicalTrials.gov (opens the registry)

   Updated Sep 25, 2026

2. Notable

   AAV5-hRKp.RPGR · X-linked Retinitis Pigmentosa

   Sponsor changed: Janssen Pharmaceutical K.K. to MeiraGTx Ocular UK Ltd

   MeiraGTx Ocular UK Ltd·Phase 3· NCT05926583· Registry history of NCT05926583 on ClinicalTrials.gov (opens the registry)

   Updated Sep 25, 2026

3. Notable

   Follow-on Study for Second-Eye Treatment for Participants…Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

   Sponsor changed: Janssen Research & Development, LLC to MeiraGTx Ocular UK Ltd

   MeiraGTx Ocular UK Ltd·Phase 2· NCT06646289· Registry history of NCT06646289 on ClinicalTrials.gov (opens the registry)

   Updated Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.